Compare Gigacloud Technology Inc (GCT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Viatris Inc — how do they compare? Gigacloud Technology Inc trades at $52.14 (market cap $1.84B), while Viatris Inc trades at $16.12 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 10.2× Gigacloud Technology Inc's market cap, and Viatris Inc pays a 2.95% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.
| GCT | VTRS | |
|---|---|---|
Market Cap | $1.84B | $18.69B |
Sector | Technology | Health |
52-Week High | $53.25 | $17.86 |
52-Week Low | $25.44 | $9.49 |
Enterprise Value | $1.97B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GigaCloud Technology (GCT) trades at $51.68, up 0.06% on the day, with a bullish technical outlook supported by moving averages and strong support at $50. The company reported Q2 2026 EPS of $1.16, beating estimates, and maintains a net income margin of 10.65%. Revenue growth is projected to rise from $1.29B in 2025 to $1.5B in 2026, while analyst sentiment is positive with a 66.7% buy rating.
The stock presents a compelling opportunity due to consistent earnings beats, robust profitability metrics like a 32.34% ROE, and attractive valuation with a P/E of 12.25. Key risks include reliance on B2B furniture logistics, competitive pressures, and potential margin compression from higher costs. Institutional confidence is bolstered by a $120M buyback program announced in Q2 2026.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
